Condition

B-cell Malignancies clinical trials and research

• 8Clinical trials
• 11Countries

Newest B-cell Malignancies clinical trials

All recruiting trials (8)

• CD19-targeted mRNA therapy delivered by lipid nanoparticles for B-cell blood cancers

  It will try a lipid-nanoparticle mRNA therapy that generates CD19-targeted CAR-T activity inside the body for adults (18–70) with relapsed or refractory CD19-positive B-cell leukemia or lymphoma who have no standard treatment options.

  Recruiting Early Phase 1 Xinqiao Hospital of Chongqing · Chongqing, Chongqing Municipality · NCT07349849

• Emavusertib plus zanubrutinib for CLL and other B‑cell cancers

  This test will see if adding emavusertib to the BTK inhibitor zanubrutinib can reduce measurable residual disease in adults with chronic lymphocytic leukemia or other B‑cell malignancies.

  Recruiting at 11 sites Phase 2 Curis, Inc. · Miami Beach, Florida and 10 other locations · NCT07271667

• Anti-CD22 CAR‑T cell therapy for CD22‑positive B‑cell cancers

  This trial will try a one-time CAR‑T cell therapy that targets CD22 in children and adults whose relapsed or refractory B‑cell cancers still express CD22 after prior treatments, including CD19‑directed therapy.

  Recruiting Phase 1/2 Sheba Medical Center · Ramat Gan, G · NCT07135466

• JY231 injection for relapsed or refractory CD19-positive B-cell malignancies

  This trial will test whether a single intravenous injection of JY231, an in vivo CAR-T therapy, can help adults with relapsed or refractory CD19-positive B-cell malignancies.

  Recruiting 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Kunming, Yunnan · NCT07065279

• Evaluating SYS6005 for advanced malignant tumors

  This study is testing a new treatment called SYS6005 to see if it is safe and effective for people with advanced malignant tumors.

  Recruiting Phase 1 CSPC Megalith Biopharmaceutical Co.,Ltd. · Tianjin · NCT06958679

• Evaluating a new T cell-engaging antibody for B-cell cancers

  This study is testing a new antibody treatment for people with tough-to-treat B-cell cancers to see if it is safe and effective after they have already tried other therapies.

  Recruiting at 30 sites Phase 1/2 AstraZeneca · La Jolla, California and 30 other locations · NCT06542250

• Treatment with anti-CD19-CAR-T cells for patients with relapsed B-cell tumors

  This study is testing a new treatment using anti-CD19-CAR-T cells to see if it can help patients with relapsed B-cell tumors feel better.

  Recruiting Early Phase 1 Shanghai Tongji Hospital, Tongji University School of Medicine · Shanghai, Shanghai Municipality · NCT06375161

• Evaluating TT-01488 for treating B-cell malignancies

  This study is testing a new drug called TT-01488 to see if it can safely help adults with B-cell cancers.

  Recruiting Phase 1 TransThera Sciences (Nanjing), Inc. · Nanjing, Jiangsu · NCT05683717

Related topics

Quick answers

How many B-cell Malignancies clinical trials are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in China (6 trials), Italy (2 trials), Spain (2 trials), United States (2 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Early Phase 1: 2, Phase 1: 2, Phase 1/2: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →